Valneva: positive data from chikungunya vaccine

(CercleFinance.com) - The vaccine company Valneva today announced positive data on antibody persistence twelve months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553.


After the announcement of positive immunogenicity and safety data for the Phase 3 VLA1553-301 study in March 2022, Valneva initiated an antibody persistence trial (VLA1553-303) to follow a subset of participants for a period of at least five years and confirm the long-term durability of the antibody response after a single vaccination.

This antibody persistence trial involved 363 healthy adult participants who were monitored between the sixth and twelfth month after vaccination.

99% of the participants maintained neutralising antibody titres above the seroresponse threshold of 150 one year after a single vaccination.


Copyright (c) 2022 CercleFinance.com. All rights reserved.